CN101904807B - 包含植物提取物的化妆品成分 - Google Patents
包含植物提取物的化妆品成分 Download PDFInfo
- Publication number
- CN101904807B CN101904807B CN2009101399732A CN200910139973A CN101904807B CN 101904807 B CN101904807 B CN 101904807B CN 2009101399732 A CN2009101399732 A CN 2009101399732A CN 200910139973 A CN200910139973 A CN 200910139973A CN 101904807 B CN101904807 B CN 101904807B
- Authority
- CN
- China
- Prior art keywords
- skin
- purposes according
- dosage form
- cosmetics
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 239000000419 plant extract Substances 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 48
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 37
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000008591 skin barrier function Effects 0.000 claims abstract description 17
- 244000265913 Crataegus laevigata Species 0.000 claims abstract description 14
- 235000013175 Crataegus laevigata Nutrition 0.000 claims abstract description 14
- 235000017156 Crataegus rhipidophylla Nutrition 0.000 claims abstract description 14
- 240000003409 Gentiana lutea Species 0.000 claims abstract description 14
- 235000002873 Gentiana lutea Nutrition 0.000 claims abstract description 14
- 229960001340 histamine Drugs 0.000 claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 claims abstract description 13
- 230000004054 inflammatory process Effects 0.000 claims abstract description 13
- 238000011084 recovery Methods 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims description 23
- 239000006071 cream Substances 0.000 claims description 18
- 241000173256 Cymbidium kanran Species 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 230000001815 facial effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- -1 pastel Substances 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000012459 cleaning agent Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 210000002950 fibroblast Anatomy 0.000 abstract description 7
- 201000004624 Dermatitis Diseases 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 206010012434 Dermatitis allergic Diseases 0.000 abstract description 3
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 2
- 240000005186 Cymbidium lancifolium Species 0.000 abstract 1
- 240000000982 Malva neglecta Species 0.000 abstract 1
- 235000000060 Malva neglecta Nutrition 0.000 abstract 1
- 235000011203 Origanum Nutrition 0.000 abstract 1
- 241001529744 Origanum Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 18
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 16
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 15
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229940058015 1,3-butylene glycol Drugs 0.000 description 9
- 235000019437 butane-1,3-diol Nutrition 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 8
- 229920001214 Polysorbate 60 Polymers 0.000 description 8
- 229960000458 allantoin Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 8
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 8
- 229940113124 polysorbate 60 Drugs 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 7
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 7
- 229940032094 squalane Drugs 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 6
- 229940079894 benzophenone-9 Drugs 0.000 description 6
- 229940008099 dimethicone Drugs 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 6
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 229950011392 sorbitan stearate Drugs 0.000 description 6
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003974 emollient agent Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000036560 skin regeneration Effects 0.000 description 4
- 229940075554 sorbate Drugs 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 235000006770 Malva sylvestris Nutrition 0.000 description 3
- 240000002129 Malva sylvestris Species 0.000 description 3
- 240000007673 Origanum vulgare Species 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 2
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000003912 basophilic leucocyte Anatomy 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940049294 glyceryl stearate se Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000077 insect repellent Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical class [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940041022 streptomycins Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DBOVHQOUSDWAPQ-UHFFFAOYSA-N (4aS)-6c-[O2-(3,5,3'-trihydroxy-biphenyl-2-carbonyl)-beta-D-glucopyranosyloxy]-5t-vinyl-(4ar)-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-1-one Natural products OC1C(O)C(CO)OC(OC2C(C3C(C(OCC3)=O)=CO2)C=C)C1OC(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- KQIKOUUKQBTQBE-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KQIKOUUKQBTQBE-UHFFFAOYSA-N 0.000 description 1
- BZXINCMCFVKGKB-UHFFFAOYSA-N Amarogentin Natural products OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)c4cc(O)cc(O)c4c5cccc(O)c5)C(O)C1O BZXINCMCFVKGKB-UHFFFAOYSA-N 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- YYVIFBVXJYYHCW-UHFFFAOYSA-N Malvin Natural products COc1cc(cc(OC)c1O)C2=C(Cc3c(OC4OC(CO)C(O)C(O)C4O)cc(O)cc3O2)OC5OC(CO)C(O)C(O)C5O YYVIFBVXJYYHCW-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- DBOVHQOUSDWAPQ-WTONXPSSSA-N amarogentin Chemical compound O([C@H]1[C@H](O[C@H]2[C@@H]([C@H]3C(C(OCC3)=O)=CO2)C=C)O[C@@H]([C@H]([C@@H]1O)O)CO)C(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-WTONXPSSSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- CILLXFBAACIQNS-BTXJZROQSA-O malvin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 CILLXFBAACIQNS-BTXJZROQSA-O 0.000 description 1
- 229940117886 malvin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011175 product filtration Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- MDBKCNBPGJPWMA-UHFFFAOYSA-N xanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1.C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 MDBKCNBPGJPWMA-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/044—Suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开一种含有植物提取物的化妆品成分,特别涉及一种将寒兰、黄龙胆、锦葵、牛至及锐刺山楂的提取物作为有效成分的含有植物提取物的化妆品成分。根据本发明的成分,可抑制与炎症反应有关的氧化氮、组胺的分泌、缓和皮肤炎症、促进成纤维细胞增殖、改善皮肤弹性及皮肤皱纹、优秀的受损皮肤屏障的恢复效果。由此,可用作过敏性皮炎等的皮肤炎症的缓解、皮肤老化的防止、皮肤再生的促进、皮肤保湿等的各种机能性化妆品成分。
Description
技术领域
本发明涉及一种化妆品成分,特别涉及一种包含可抑制与炎症反应有关的氧化氮、组胺的分泌、缓和皮肤炎症、促进成纤维细胞增殖、改善皮肤弹性及皮肤皱纹、优秀的受损皮肤屏障恢复效果的植物提取物的化妆品组成分。
背景技术
皮肤是有表皮、真皮、皮下脂肪层此3个层所形成。位于表皮最外层的角质层提供低渗透性和物理屏障机能,可从外部环境保护人体,防止水分损失、具有对毒性物质或微生物、机械刺激、紫外线的屏障作用。
这种皮肤,其生理机能随着年龄的增加反而急剧降低,由此皮肤细胞的增殖变得缓慢、阻碍脂质成分的合成,由此导致了皮肤老化及干燥。并且,在人体内大量发生由于紫外线照射、生体内代谢过程中所产生的自由基引起的损伤,特别是产生脂质成分的过氧化物而破坏皮肤脂质结构,由此导致了皮肤屏障机能的降低、皮肤受损,加快了皮肤老化、干燥。特别是,被认为是最近发病率明显增加的过敏/特应性(Atopy)皮炎的皮肤屏障异常的重要原因。
为解决损伤皮肤屏障机能,揭示有从外部提供水分或者最小化体内水分损失而使皮肤维持适当的水分,或使用通过类似于人体皮脂的成分来组合脂质成分的化妆品的常用技术。
但是,这些方法是属于临时性的皮肤保护效果而不是根治方法,重要的是开发出通过提高皮肤自身机能来恢复受损皮肤屏障的物质。
并且,因存在生体组织对外部物质的防御作用,炎症表现出以下外部症状,即,局部血管或体液内的炎症因子及免疫细胞的活化、炎症因子的分泌、体液渗透(infiltrate)、免疫细胞的移动、组织破坏等生理反应,和红斑、浮肿、发热、痛症等外部症状。
炎症反应的主要原因有微生物感染、过敏反应、物理原因、化学原因及组织坏死等。特别是,由于氧化氮合成酶(nitric oxidesynthase;NOS)而产生的氧化氮(nitric oxide;NO)和肥大细胞所分泌的组胺(histamine)是诱发炎症反应的主要传递物质。因此,可抑制肥大细胞所分泌的组胺的分泌、或可减少产生氧化氮的物质,不仅适用于一般炎症反应,还可向过敏性皮炎等的皮肤炎症的缓解提供适当的功效。
本发明的发明人发现,黄龙胆(Gentiana lutea)、锦葵(Malvasylvestris)、牛至(oregano vulgare)及锐刺山楂(Crataegusoxyacantha)的提取物可缓解月桂醇聚醚硫酸酯钠盐(sodiumlaureth sulfate)的皮肤刺激,进而在韩国申请了包含这些提取物的皮肤刺激缓解用化妆品成分的发明专利,并取得了大韩民国发明专利登录第10-0782517号的专利权。
并且,本发明的发明人基于上述提取物对机能性化妆品成分的用途进行多方面的研究,发现将寒兰(cymbidium kanran makino)与上述提取物同时使用时,可抑制与炎症反应有关的氧化氮、组胺的分泌、促进成纤维细胞的增殖、具有优秀的受损皮肤屏障的恢复效果,并基于此完成本发明。
发明内容
鉴于上述问题的不足,本发明的目的在于提供一种可具有缓解皮肤炎症、促进皮肤再生、受损皮肤屏障的恢复效果的化妆品成分。
本发明是以如下方式实现的,本发明的包含植物提取物的化妆品成分,有效成分中包含寒兰、黄龙胆、锦葵、牛至及锐刺山楂的提取物。
本发明的包含植物提取物的化妆品成分,具有可缓解皮肤炎症、促进成纤维细胞的增殖、促进皮肤再生、优秀的受损皮肤屏障的恢复效果。从而可用作诸如为缓解过敏性皮肤炎等的皮肤炎症、防止皮肤老化、促进皮肤再生、皮肤保湿等的各种机能性化妆品成分。
具体实施方式
本发明中所述的“皮肤炎症”是指一般的各种皮肤炎,包括过敏性(allergic)皮炎、特应性(atopy)皮炎、接触性皮炎。
本发明的化妆品成分,作为有效成分而包含寒兰(Cymbidiumkanran Makino)、黄龙胆(Gentiana lutea)、锦葵(Malvasylvestris)、牛至(oregano vulgare)、锐刺山楂(Crataegusoxyacantha)的提取物。此时的提取物,是从各种植物的多种器官或部位题去的,可以是叶、花、根、茎、枝、皮及种子等的提取物。
寒兰(Cymbidium kanran Makino)分为单叶子植物(Liliopsida)的兰科兰属常绿多年生植物,因寒冷时开花而起名寒兰。分布地区为韩国济州南侧,叶呈线型且向后弯曲,长度为20~70cm,宽度为6~17mm,末端尖细、边缘大致平滑。寒兰的所有部位均可使用,优选为使用叶子。
黄龙胆(Gentiana lutea)是具有茎和椭圆形叶子的多年生植物,大小约为1.8m,优选使用部分干燥的根茎或根。主要成分有多酚(polyphenol)、多糖(polysaccharide)、龙胆苦甙(gentiopicroside)、苦杏苷(Amarogentin)、呫吨酮(xanthone)等。
锦葵(Malva sylvestris)原产地为亚洲,高度为69~90cm。叶子呈相互错开的圆形,分支为5~9个,在边缘有小锯齿。可利用的部分是叶子、根、花,其中优选使用花部分。主要成分有花青素(anthocyanin)(锦葵花甙、锦葵色素)、黄酮类(flavonoid)、单宁酸(tannin)、维他命A、维他命B1、维他命B2、维他命C、维他命E等。
牛至(Origanum vulgare)为多年生植物,具有枝,且大小约为0.9m,可利用干燥的植物和叶子,其中优选使用叶子。牛至提取物,因在制备面包时提高面包的香味、具有细菌(bacteria)活性抑制效果而常用作制备面包等时的食品添加剂。主要成分有黄酮类(flavonoid)、咖啡酸衍生物、单宁酸(tannin)成分等。
锐刺山楂(Crataegus oxyacantha)具有血管扩充作用、降压作用、强心作用或促进消化作用、健胃作用、止泻作用、阵痛作用等。优选利用部分为干燥的果实,果实中含有熊果酸(ursolic acid)、齐墩果酸(oleanolic acid)、芸香苷(rutin)等,种子中含有苦杏仁苷(amygdalin)、金丝桃甙(hyperin)、脂肪油,树皮中含有七叶苷(Aesculin)。
作为本发明化妆品成分的有效成分的提取物,可通过本技术领域公知方法,即,使用常规溶剂,并以常规使用的热水提取、室温提取、加温提取、超声波提取、超临界提取等方法制备。
优选为,使用水、C1~C6的低级甘醇(lower glycol)、C1~C4的低级醇(lower alcohol)及它们的混合物构成的组中选择的溶剂来进行提取。最优选为,以1,3-丁二醇为提取溶剂,在室温条件下通过超声波提取机提取1~12个小时,上述超声波提取的时间可根据所提取试样的量不同,可进行将提取产物过滤或提纯(purification)的工序。
本发明的成分中,提取物含量占化妆品成分总重量的0.001~30.0重量%,优选为0.1~5.0重量%。如果上述提取物含量未满上述范围,则产生的效果不理想,与此相反,如果超过上述范围,则存在随着含量增加的效果不明显,使得剂型稳定性降低。
优选为,本发明包含从占30~70重量%的寒兰、占5~15重量%的黄龙胆、占5~10重量%的锦葵、占1~10重量%的牛至及占20~40重量%的锐刺山楂形成的混合原料中提取的提取物。并且,优选为,本发明的化妆品成分包含占30~70重量%的寒兰提取物、占5~15重量%的黄龙胆提取物、占5~10重量%的锦葵提取物、占1~10重量%的牛至提取物及占20~40重量%的锐刺山楂提取物。这种混合比例,是可最大化本发明的化妆品成分的皮肤刺激及炎症缓解效果的范围。
本发明的化妆品成分,可制备成公知的任意剂型,具体说明是,可通过溶液、悬浮液、乳剂(emulsion)、糊状物(paste)、胶、面霜(cream)、乳液(lotion)、粉末(powder)、肥皂(soap)、含表面活性剂的清洁剂(cleansing)、油、粉末粉底、乳剂粉底、蜡粉底(wax foundation)及喷雾形(spray)来剂型化。
并且,各剂型的成分可包含对该制剂的制剂化所需的各种基质和添加物,在不降低该效果的范围内可包含如下公知成分来制备:非离子表面活性剂、硅聚合物(silicon polymer)、体质颜料、香料、防腐剂、杀菌剂、氧化稳定剂、有机溶剂、离子型非离子型增黏剂(viscosity agent)、柔软剂、防氧化剂、自由基清除剂、不透明剂、稳定剂、润肤剂(emollient)、硅、α-羟基酸(alpha hydroxy acid)、消泡剂、保湿剂、维他命、昆虫驱避剂(Insect repellant)、香料、保存剂、表面活性剂、消炎剂、P物质(Substance P)、填充剂、聚合体、燃料(fuel)、碱性化剂或酸性化剂、或者着色剂等。
本发明的上述混合提取物具有突出的抗炎效果(参照试验例1及2),具有突出的细胞增殖效果(参照试验例3)、具有优秀的皮肤屏障恢复能力(参照试验例5)。
实施例
以下,为便于理解本发明而揭示优选实施例及比较例。但是,下述实施例是为更容易理解本发明而提供的,本发明的保护范围并不限于下述实施例。
制造例1:寒兰、黄龙胆、锦葵、牛至及锐刺山楂混合提取物的制备
将寒兰50g、黄龙胆10g、锦葵7.5g、牛至2.5g及锐刺山楂30g混合,利用搅拌机进行粉碎,而后添加40%的1,3-丁二醇(1,3-Butylene glycol)水溶液1000ml,并在室温条件下以超声波提取机提取4个小时。利用过滤纸(沃特曼公司的3号过滤纸,WhatmanPaper Filter No.3)进行一次减压过滤,冷藏保存2天,发生沉淀物后通过二次减压过滤获得混合提取物。
实施例1~实施例3及比较例1
以上表1的组成,通过常规方法来制备实施例1~实施例3及比较例1的乳剂(emulsion)成分。
【表1】
成分含量(重量%) | 实施例1 | 实施例2 | 实施例3 | 比较例1 |
混合提取物 | 1.0 | 5.0 | 10.0 | - |
甘油(glycerin) | 5.1 | 5.1 | 5.1 | 5.1 |
丙二醇(propylene glycol) | 4.2 | 4.2 | 4.2 | 4.2 |
生育酚乙酸酯(Tocopherylacetate) | 3.0 | 3.0 | 3.0 | 3.0 |
液体石蜡(liquidpetrolatum) | 4.6 | 4.6 | 4.6 | 4.6 |
三乙醇胺(Triethanolamine) | 1.0 | 1.0 | 1.0 | 1.0 |
角鲨烷(Squalane) | 3.1 | 3.1 | 3.1 | 3.1 |
夏威夷果油(macadamia nutoil) | 2.5 | 2.5 | 2.5 | 2.5 |
聚山梨醇酯60(Polysorbate 60) | 1.6 | 1.6 | 1.6 | 1.6 |
失水山梨糖醇倍半油酸酯(sorbitan sesquioleate) | 1.6 | 1.6 | 1.6 | 1.6 |
尼伯金丙酯(propylparaben) | 0.6 | 0.6 | 0.6 | 0.6 |
聚羧乙烯(carboxyvinyl | 1.5 | 1.5 | 1.5 | 1.5 |
polymer) | ||||
纯净水(purified water) | 残量 | 残量 | 残量 | 残量 |
合计 | 100 | 100 | 100 | 100 |
试验例1:氧化氮分泌量抑制效果的确认
为了对根据本发明的提取物的皮肤炎症缓解效果进行评价,测定了氧化氮(nitric oxide;NO)分泌量的变化。
将作为老鼠的巨噬细胞(macrophage)的Raw 264.7细胞,在DMEM(Dulbecco’s Modified Eagle’s Medium)培养基中添加10%胎牛血清(fetal bovine serum,FBS)、100units/mL青霉素(penicillin)和100μg/mL链霉素(streptomycine)的条件下,在培养基(37℃、5%CO2)进行培养。
细胞成长到100mm培养皿(dish)底板的大致80%时,为诱导细胞炎症反应而向含有1%胎牛血清的DMEM培养液中添加脂多糖(lipopolysaccharide),直至DMEM培养液达到100ng/ml。
在Raw 264.7细胞中添加上述制造例1的提取物或脂多糖并培养24个小时,而后收集该培养液,利用格里斯试剂(Griess reagent)测定了氧化氮的分泌量(Kim JK et al.,Biochem Biophys ResCommun.,345,pp1215-1223,2006),其结果如下表2所示。
【表2】
混合提取物浓度(ug/ml) | 对照组 | 1 | 5 | 10 | 20 |
氧化氮分泌量(相对对照组分泌量的%%) | 100 | 91 | 68 | 61 | 47 |
如上表2所示,对本发明的提取物进行处理时,通过浓度条件来减少以脂多糖诱导的氧化氮的生成。
通过这些结果可知,在使用本发明提取物的情况下可有效缓解皮肤炎症。
试验例2:组胺(histamine)分泌量抑制效果的确认
为了对根据本发明的提取物的皮肤炎症缓解效果进行分析,测定了组胺分泌量的变化。
众所周知,组胺是与白细胞介素-2(interleukin-2)、P物质(substance P)、阿片肽(opioid peptide)、前列腺素E(prostagladinE)等进行炎症反应的媒质(mediator),主要在肥大细胞(mast cell)游离而诱发发痒和疼痛。从而,因组胺具有这些分泌抑制能力而用于对炎症反应和发痒、疼痛等一系列炎症诱发反应进行抑制。
将作为老鼠的嗜碱白细胞(basophil)的RBL-2H3细胞,在EMEM(Eagles Minimum Essential Medium)培养基中添加10%胎牛血清(fetal bovine serum,FBS)、100units/mL青霉素(penicillin)和100μg/mL链霉素(streptomycine)的条件下,在培养基(37℃、5%CO2)进行培养。
细胞成长到100mm培养皿(dish)底板的大致80%时,进行胰蛋白酶細胞消化液(Trypsin-Versene)处理而提取细胞,将2×106个细胞接种到24孔板(well plate)并培养18个小时。去除培养基后放入包含有IgE(0.2ug/ml)的EMEM培养基并培养1个小时,将添加含有Anti-IgE的release buffer 0.2ml反应10分钟。将释放的组胺在放射线免疫测定仪器(radioimmunoassay kit,Immunotech,Marseille,France)定量,其结果如下表3所示。
【表3】
混合提取物浓度(ug/ml) | 对照组 | 1 | 5 | 10 | 20 |
组胺分泌量(相对对照组分泌量的%%) | 100 | 94 | 71 | 62 | 56 |
如上表3所示,本发明的提取物处理组,可通过浓度条件来抑制以老鼠嗜碱白细胞的分泌量。通过这些结果可知,在使用本发明提取物的情况下可有效缓解皮肤炎症。
试验例3:细胞增殖促进效果的确认
在96微孔板(96-well microplate)的各孔板接种1×104个人体正常成纤维细(fibroblast),并在DMEM培养基中培养24个小时。
在培养后,将实施例所制备的上述混合提取物,通过调节成最终浓度为1、5、10、20μg/ml的无血清的EMEM培养基进行交替,而后进一步培养24个小时。分别添加MTT溶液(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazoliumbromide:5mg/ml)10μl,并放置4个小时后去除培养基部分。按各孔板添加100μl二甲基亚砜(dimethyl sulfoxide)溶液中并搅拌5分钟,而后用酶标仪(microplate reader)在570nm测定了吸光度。通过吸光度测定的人体成纤维细胞的增殖率是以如下数学式1计算的,其结果如下表4所示。
【数学式1】
细胞增殖率(%)=(提取物处理时的吸光度/对照组的吸光度)×100
【表4】
混合提取物的浓度(ug/ml) | 对照组 | 1 | 5 | 10 | 20 |
细胞增殖率(%) | 100 | 105 | 110 | 124 | 131 |
如上表4所示,本发明的提取物可通过浓度条件来增加了人体正常成纤维细胞的细胞增殖。通过这些结果可知,本发明的提取物可促进皮肤再生,对皮肤皱纹及弹性改善有良好的效果。
试验例4:化妆品剂型根据温度变化的稳定性试验
对本发明的化妆品剂型根据温度变化的稳定性进行了试验。对上述实施例1~实施例3和比较例1的化妆品剂型,分别通过4℃、45℃、50℃、Cycle(4℃~45℃)的恒温槽及室温条件下,以1周、1个月、6个月为单位进行长期保存,通过下表5的评建标准对该长期保存的安定性进行了分析。
稳定:○,不稳定:△,分离:×
【表5】
如上表5所示,未含有混合提取物的比较例1的剂型的稳定性良好,由此可知剂型其他成分无稳定性隐患,含有1%混合提取物的实施例1的剂型与含有5%以上的实施例2~实施例3的剂型相比,其长期保存稳定性和未含混合提取物的比较例1的剂型相同地,具有非常优秀的长期保存稳定性。
试验例5:皮肤屏障恢复效果的确认
为分析皮肤屏障损伤的恢复情况,以健康女性20名为对象通过以下方法进行了试验。
首先,将被试验者分为两个组,即各10名,通过斑贴试验(TapeStripping)方法弱化了待试验部位的皮肤屏障功能。之后组1涂抹实施例1的化妆品,组2涂抹比较例1的化妆品,以每天2次的频率涂抹1周,对皮肤屏障的恢复情况利用TEWA mater(CorneometerCM820,Conrage+Khazaka公司,德国)测定了经皮水分损失量(TransEpidermalWaterLoss:TEWL)的值,其结果如下表6所示。
【表6】
区分 | TEWL(g/m2/h) |
实施例1 | 15 |
比较例1 | 33 |
如上表6所示,包含根据本发明的混合提取物的化妆品可提高皮肤屏障脂质成分的正常生体能力,从而其改善损伤皮肤屏障的效果非常优秀。
以下,作为本发明的处方例,例示有柔软化妆水、收敛化妆水、营养化妆水、营养面霜、按摩面霜、香水(essence)及润肤霜(pack),而本发明的化妆品成分的剂型并不限于上述例子。
剂型例1:柔软化妆水(皮肤乳液)
如下表7所示,通过常规方法制备了柔软化妆水。
【表7】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
甘油(glycerin) | 5.0 |
1,3-丁二醇(1,3-Butylene glycol) | 3.0 |
PEG 1500 | 1.0 |
尿囊素(allantoin) | 0.1 |
DL-泛醇(dl-panthenol) | 0.3 |
EDTA-2Na | 0.02 |
二苯酮-9(Benzophenone-9) | 0.04 |
透明质酸钠(sodium hyaluronate) | 5.0 |
乙醇(ethanol) | 10.0 |
辛基十二醇聚醚-16(Octyldodeceth-16) | 0.2 |
山梨酸盐20(sorbate 20) | 0.2 |
Unicide U-13 | 0.01 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例2:收敛化妆水
如下表8所示,通过常规方法制备了收敛化妆水。
【表8】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
甘油(glycerin) | 2.0 |
1,3-丁二醇(1,3-Butylene glycol) | 2.0 |
尿囊素(allantoin) | 0.2 |
DL-泛醇(dl-panthenol) | 0.2 |
EDTA-2Na | 0.02 |
二苯酮-9(Benzophenone-9) | 0.04 |
透明质酸钠(sodium hyaluronate) | 3.0 |
乙醇(ethanol) | 15.0 |
山梨酸盐20(sorbate 20) | 0.3 |
金缕梅(witch hazel)提取物 | 2.0 |
柠檬酸(citric acid) | 微量 |
Unicide U-13 | 0.01 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例3:营养化妆水
如下表9所示,通过常规方法制备了营养化妆水。
【表9】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
甘油硬脂酸酯SE(Glyceryl Stearate SE) | 1.5 |
硬脂醇(stearyl Alcohol) | 1.5 |
羊毛脂(lanolin) | 1.5 |
聚山梨醇酯60(Polysorbate 60) | 1.3 |
山梨醇硬脂酸酯(sorbitan stearate) | 0.5 |
硬化植物油 | 1.0 |
矿物油 | 5.0 |
角鲨烯(squalane) | 3.0 |
三辛酸甘油酯(trioctanoin) | 2.0 |
二甲聚硅氧烷(dimethicone) | 0.8 |
盐酸生育酚酯(Tocopherol acetate) | 0.5 |
聚羧乙烯(carboxyvinyl polymer) | 0.12 |
甘油(glycerin) | 5.0 |
1,3-丁二醇(1,3-Butylene glycol) | 3.0 |
透明质酸钠(sodium hyaluronate) | 5.0 |
三乙醇胺(Triethanolamine) | 0.12 |
Unicide U-13 | 0.02 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例4:营养面霜
如下表10所示,通过常规方法制备了营养面霜。
【表10】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
亲油性单硬脂酸甘油酯(GlycerinMonostearate,Lipophilic) | 2.0 |
硬脂醇(stearyl Alcohol) | 2.2 |
硬脂酸(Stearic acid) | 1.5 |
蜂蜡(beeswax) | 1.0 |
聚山梨醇酯60(Polysorbate 60) | 1.5 |
山梨醇硬脂酸酯(sorbitan stearate) | 0.6 |
硬化植物油 | 1.0 |
角鲨烷(Squalane) | 3.0 |
矿物油 | 5.0 |
三辛酸甘油酯(trioctanoin) | 5.0 |
二甲聚硅氧烷(dimethicone) | 1.0 |
硅酸镁钠(sodium magnesium silicate) | 0.1 |
甘油(glycerin) | 5.0 |
内胺盐(Betaine) | 3.0 |
三乙醇胺(Triethanolamine) | 1.0 |
透明质酸钠(sodium hyaluronate) | 4.0 |
Unicide U-13 | 0.02 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例5:按摩面霜
如下表11所示,通过常规方法制备了按摩面霜。
【表11】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
亲油性单硬脂酸甘油酯(GlycerinMonostearate,Lipophilic) | 1.5 |
硬脂醇(stearyl Alcohol) | 1.5 |
硬脂酸(Stearic acid) | 1.0 |
聚山梨醇酯60(Polysorbate 60) | 1.5 |
山梨醇硬脂酸酯(sorbitan stearate) | 0.6 |
异硬脂酰异硬脂酸盐(isostearylisostearate) | 5.0 |
角鲨烷(Squalane) | 5.0 |
矿物油 | 35.0 |
二甲聚硅氧烷(dimethicone) | 0.5 |
羟乙基纤维素(hydroxyethyl cellulose) | 0.12 |
甘油(glycerin) | 6.0 |
三乙醇胺(Triethanolamine) | 0.7 |
Unicide U-13 | 0.02 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例6:香水
如下表12所示,通过常规方法制备了香水。
【表12】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
甘油(glycerin) | 10.0 |
内胺盐(Betaine) | 5.0 |
PEG 1500 | 2.0 |
尿囊素(allantoin) | 0.1 |
DL-泛醇(dl-panthenol) | 0.3 |
EDTA-2Na | 0.02 |
二苯酮-9(Benzophenone-9) | 0.04 |
羟乙基纤维素(hydroxyethyl cellulose) | 0.1 |
透明质酸钠(sodium hyaluronate) | 8.0 |
聚羧乙烯(carboxyvinyl polymer) | 0.2 |
三乙醇胺(Triethanolamine) | 0.18 |
辛基十二碳醇(Octyldodecanol) | 0.3 |
辛基十二醇聚醚-16(Octyldodeceth-16) | 0.4 |
乙醇 | 6.0 |
Unicide U-13 | 0.01 |
蒸馏水 | 残量 |
合计 | 100 |
剂型例7:润肤霜
如下表13所示,通过常规方法制备了润肤霜。
【表13】
成分 | 含量(重量%) |
混合提取物 | 0.3 |
聚乙烯醇(polyvinyl alcohol) | 15.0 |
纤维素胶(cellulose gum) | 0.15 |
甘油(glycerin) | 3.0 |
PEG 1500 | 2.0 |
环糊精(Cyclodextrin) | 0.15 |
DL-泛醇(dl-panthenol) | 0.4 |
尿囊素(allantoin) | 0.1 |
甘草酸单铵盐(Ammonium Glycyrrhizinate) | 0.3 |
烟酰胺(nicotinamide) | 0.5 |
乙醇(ethanol) | 6.0 |
PEG 40硬化蓖麻油(castor oil) | 0.3 |
Unicide U-13 | 0.02 |
蒸馏水 | 残量 |
合计 | 100 |
Claims (8)
1.寒兰、黄龙胆、锦葵、牛至及锐刺山楂的提取物作为有效成分在制备抑制与炎症反应有关的氧化氮、组胺的分泌的化妆品中的用途,其中,上述提取物是从寒兰占30~70重量份、黄龙胆占5~15重量份、锦葵占5~10重量份、牛至占1~10重量份、锐刺山楂占20~40重量份的混合原料所提取的,上述提取物是通过从水、C1~C6的低级二醇、C1~C4的低级醇及它们的混合物构成的组中选择的一种提取溶剂来提取的。
2.根据权利要求1所述的用途,其中,上述提取物的含量占化妆品总重量的0.001~30重量%。
3.根据权利要求1所述的用途,其中,上述化妆品是用于皮肤炎症的缓解。
4.根据权利要求1所述的用途,其中,上述化妆品是用于皮肤屏障的恢复。
5.根据权利要求1所述的用途,其中,上述化妆品具有从溶液、悬浮液、乳剂、糊状物、胶、粉末、肥皂、油、蜡粉底及喷雾剂构成的组中选择的一种剂型。
6.根据权利要求1所述的用途,其中,上述化妆品具有从面霜、粉末粉底、乳剂粉底构成的组中选择的一种剂型。
7.根据权利要求1所述的用途,其中,上述化妆品具有乳液剂型。
8.根据权利要求1所述的用途,其中,上述化妆品具有含表面活性剂的清洁剂的剂型。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090049615A KR101100678B1 (ko) | 2009-06-04 | 2009-06-04 | 식물 추출물을 함유하는 화장료 조성물 |
KR10-2009-0049615 | 2009-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101904807A CN101904807A (zh) | 2010-12-08 |
CN101904807B true CN101904807B (zh) | 2013-07-03 |
Family
ID=43260500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101399732A Withdrawn - After Issue CN101904807B (zh) | 2009-06-04 | 2009-07-17 | 包含植物提取物的化妆品成分 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101100678B1 (zh) |
CN (1) | CN101904807B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101832283B1 (ko) * | 2012-01-13 | 2018-02-26 | 주식회사 엘지생활건강 | 피부 주름 개선 및 탄력 증진용 조성물 |
KR101460901B1 (ko) * | 2013-06-27 | 2014-11-13 | 주식회사 엘지생활건강 | 아마로젠틴을 포함하는 피부 미백, 재생 또는 보습용 화장료 조성물 |
KR102142318B1 (ko) * | 2013-11-19 | 2020-08-10 | (주)아모레퍼시픽 | 천연식물 추출물을 유효성분으로 함유하는 조성물, 이를 포함하는 피부 외용제, 이를 포함하는 화장료 및 이를 포함하는 약제 |
CN103830153B (zh) * | 2014-03-27 | 2015-11-18 | 广东伊茗药业有限公司 | 一种保湿化妆品及其制备方法 |
CN104367502A (zh) * | 2014-10-24 | 2015-02-25 | 广州丹奇日用化工厂有限公司 | 一种植物组合物提取液及其提取方法和应用 |
KR101587447B1 (ko) * | 2015-06-12 | 2016-01-21 | 조영희 | 초임계추출조건으로 추출한 추출물, bl-s를 포함하는 피부유분조절, 피부장벽강화, 피부수분조절, 피부보호효과를 지닌 화장료 조성물 |
KR102183639B1 (ko) | 2019-05-28 | 2020-11-26 | 주식회사 그린티산업 | 오레가노 오일을 유효성분으로 포함하는 두피 진정, 두피 건강, 비듬 개선용 화장료 조성물 |
CN115252483A (zh) * | 2022-08-31 | 2022-11-01 | 于永涛 | 一种参吉果油润肤组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002003336A (ja) * | 2000-06-19 | 2002-01-09 | Naris Cosmetics Co Ltd | 化粧料 |
JP2002205933A (ja) * | 2001-01-05 | 2002-07-23 | Ichimaru Pharcos Co Ltd | ラン科植物抽出物含有化粧料組成物 |
KR20070095657A (ko) * | 2006-03-22 | 2007-10-01 | (주)아르떼르화장품 | 식물 추출물을 함유하는 항산화용 또는 피부자극 완화용화장료 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4076296B2 (ja) | 1999-01-22 | 2008-04-16 | 株式会社ナリス化粧品 | 化粧料 |
KR101464745B1 (ko) * | 2008-01-29 | 2014-11-24 | 주식회사 엘지생활건강 | 난초 발효 추출물을 함유하는 피부 기능 개선 조성물 |
KR101451981B1 (ko) * | 2008-01-29 | 2014-10-21 | 주식회사 엘지생활건강 | 난초 발효 추출물을 함유하는 피부 기능 개선 조성물 |
-
2009
- 2009-06-04 KR KR1020090049615A patent/KR101100678B1/ko active IP Right Grant
- 2009-07-17 CN CN2009101399732A patent/CN101904807B/zh not_active Withdrawn - After Issue
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002003336A (ja) * | 2000-06-19 | 2002-01-09 | Naris Cosmetics Co Ltd | 化粧料 |
JP2002205933A (ja) * | 2001-01-05 | 2002-07-23 | Ichimaru Pharcos Co Ltd | ラン科植物抽出物含有化粧料組成物 |
KR20070095657A (ko) * | 2006-03-22 | 2007-10-01 | (주)아르떼르화장품 | 식물 추출물을 함유하는 항산화용 또는 피부자극 완화용화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20100130878A (ko) | 2010-12-14 |
CN101904807A (zh) | 2010-12-08 |
KR101100678B1 (ko) | 2012-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101904807B (zh) | 包含植物提取物的化妆品成分 | |
KR101773456B1 (ko) | 다단발효를 통한 생약복합발효추출물의 제조방법 및 이를 함유하는 피부 개선용 화장료 조성물 | |
KR100863890B1 (ko) | 차가버섯, 말굽잔나비버섯, 신령버섯 및 노루궁뎅이버섯혼합 추출물을 함유하는 화장료 조성물 | |
CN111712305B (zh) | 木棉树花提取物,以及含有其的化妆品、药物或皮肤病学组合物 | |
KR101208012B1 (ko) | 홍삼 먹인 달팽이 점액을 함유하는 화장료 조성물 및 그 제조방법 | |
KR102349786B1 (ko) | 주름 개선 및 미백용 화장료 조성물 | |
KR102147833B1 (ko) | 펩타이드를 함유하는 피부 개선용 화장료 조성물 | |
KR101352363B1 (ko) | 현삼추출물을 유효성분으로 함유하는 피부 보습용 외용제조성물 | |
KR20150100288A (ko) | 흑효모로 발효한 생약추출물을 함유하는 화장료 조성물 | |
KR101869096B1 (ko) | 피부보습용 및 주름개선용 화장료 조성물 | |
Venesia et al. | Effectiveness test of Centella asiatica extract on improvement of collagen and hydration in female white rat (Rattus Norwegicus Wistar) | |
CN101904808B (zh) | 具有缓解皮肤炎症及刺激效果的成分 | |
KR101827771B1 (ko) | 닥나무 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
KR102601621B1 (ko) | 복사나무 추출물을 함유하는 조성물 | |
KR102303644B1 (ko) | 울금 추출물과 식물성 혼합 추출액을 함유한 얼굴 화장용 발효 조성물 및 이의 제조방법. | |
KR100964428B1 (ko) | 약용식물 추출물을 포함하는 피부 염증 완화용 화장료조성물 | |
KR20010026175A (ko) | 천연식물 추출물을 함유하는 미백용 조성물 | |
CN115192501B (zh) | 包含稻、芦苇、玉米须、欧锦葵及芦荟提取物的皮肤保护用化妆品组合物 | |
KR102342047B1 (ko) | 질경이 추출물을 유효성분으로 함유하는 피부 보습과 탄력 효과를 갖는 화장료 조성물 | |
KR102364260B1 (ko) | 돌외, 비누풀 및 금은화 혼합추출물을 유효성분으로 함유하는 피부 진정용 화장료 조성물 | |
KR102442714B1 (ko) | 중/원적외선 조사를 이용한 에키네시아 전초 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR20160003918A (ko) | 한약재 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 | |
KR101017586B1 (ko) | 피부 미백용 화장료 조성물 | |
KR20170128766A (ko) | 닥나무 추출물을 함유하는 피부의 지질 생성 억제 및 피지 분비 감소용 화장료 조성물 | |
KR102247966B1 (ko) | 녹두씨, 만주자작나무수액 및 소리쟁이뿌리의 혼합추출물을 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
AV01 | Patent right actively abandoned |
Granted publication date: 20130703 Effective date of abandoning: 20240626 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20130703 Effective date of abandoning: 20240626 |
|
AV01 | Patent right actively abandoned | ||
AV01 | Patent right actively abandoned |